Peptide
Dasiglucagon (Zegalogue)
Dasiglucagon is a 29-amino acid glucagon analog with 7 amino acid substitutions for improved aqueous stability. FDA-approved March 2021 for severe hypoglycemia in patients 6+ with diabetes. First ready-to-use aqueous glucagon formulation (no reconstitution needed). Phase 3 trial (n=170): Median time to recovery 10 min vs 40 min placebo (P<0.001). 99% achieved plasma glucose recovery within 15 min. Also being studied for congenital hyperinsulinism.
- Updated
- How we grade
- 33 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 1
- Outcomes
- 7
- Graded outcomes
- 3310
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
Hypoglycemia
General
Key findings
- Time to Glucose Recovery (Adult)Improves (the measure goes down)
- 15-Minute Recovery RateImproves (the measure goes up)
- Pediatric EfficacyImproves (the measure goes up)
Studies cited
33 studies from PubMed
- Dasiglucagon in Children with Congenital Hyperinsulinism up to 1 Year of Age: Results from a Randomized Clinical Trial
- Necrolytic migratory erythema following prolonged continuous subcutaneous dasiglucagon administration: a rare dermatologic adverse event.
- Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.
- Letter to the Editor From He et al: "Dasiglucagon in Children With Congenital Hyperinsulinism up to 1 Year of Age: Results From a Randomized Clinical Trial".
- Response to Letter to the Editor From He et al: "Dasiglucagon in Children With Congenital Hyperinsulinism up to 1 Year of Age: Results From a Randomized Clinical Trial".
- Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children
- Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis
- Transitional Neonatal Hypoglycemia and Adverse Neurodevelopment in Midchildhood.
- Dasiglucagon: a New Hope for Managing Post-prandial Hypoglycemia After Gastric Bypass Surgery?
- Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
- Novel Use of Dasiglucagon, a Soluble Glucagon Analog, for the Treatment of Hyperinsulinemic Hypoglycemia Secondary to Suspected Insulinoma: A Case Report
- Clinical efficacy and safety of dasiglucagon in severe hypoglycemia associated with patients of type 1 diabetes mellitus: a systematic review and meta-analysis.
- Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes.
- Evaluating Ease of Use and Patient Safety of Dasiglucagon Hypo Pal Autoinjector for the Management of Hypoglycemia.
- Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies.
- Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia.
- Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis.
- Stability of the next-generation glucagon analog dasiglucagon
- Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study.
- Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial
- Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial
- Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting.
- [New Developments in Type 1 Diabetes].
- Dasiglucagon: an effective medicine for severe hypoglycemia.
- Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes.
- Dasiglucagon (Zegalogue) for severe hypoglycemia.
- New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.
- Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.
- Evaluating dasiglucagon as a treatment option for hypoglycemia in diabetes.
- Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
- Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia.
- Long-Term Safety and Tolerability of Dasiglucagon, a Stable-in-Solution Glucagon Analogue.
- American Diabetes Association - 77th Scientific Sessions (June 9-13, 2017 - San Diego, California, USA).